# Rondo Therapeutics

> Rondo Therapeutics is a Hayward, California, clinical-stage biotechnology company developing bispecific antibodies that aim to boost T-cell activity at solid tumors. Its lead candidate, RNDO-564, binds Nectin-4 on tumor cells and CD28 on T cells; it entered a Phase 1/1b trial after preclinical work centered on balancing potency with a wider therapeutic window.

- **Founded:** 2021
- **Headquarters:** Hayward, United States
- **Founders:** Shelley Force Aldred (Co-founder and CEO), Nathan Trinklein (Co-founder, president and CSO)
- **Products:** RNDO-564, RNDO-Program 2, RNDO-Program 3, RNDO-Program 4
- **Notable:** Closed a $67 million Series A in March 2022., Signed a worldwide research and license collaboration with Lilly in December 2024., Published peer-reviewed preclinical RNDO-564 research in Journal for ImmunoTherapy of Cancer in April 2025.

## Products & services

- **RNDO-564** — Investigational fully human CD28 x Nectin-4 bispecific antibody for advanced bladder cancer and other Nectin-4-associated solid tumors; in Phase 1/1b study as monotherapy and with pembrolizumab.
- **RNDO-Program 2** — Lead-optimization-stage ovarian cancer program using separate CD3 x tumor antigen and CD28 x distinct tumor antigen bispecific antibodies.
- **RNDO-Program 3** — Lead-optimization-stage endometrial cancer program involving CD3 and CD28 targeting; additional target undisclosed.
- **RNDO-Program 4** — Lead-optimization-stage renal cancer program involving CD3 and CD28 targeting; additional target undisclosed.

## Achievements

- Closed a $67 million Series A in March 2022.
- Signed a worldwide research and license collaboration with Lilly in December 2024.
- Published peer-reviewed preclinical RNDO-564 research in Journal for ImmunoTherapy of Cancer in April 2025.
- Dosed the first patient in the RNDO-564 Phase 1/1b trial in December 2025.

## Latest updates

- **2026-05** — ASCO published a trials-in-progress abstract detailing the ongoing RNDO-564 Phase 1/1b study.
- **2025-12** — Rondo announced that the first patient had received RNDO-564 in its Phase 1/1b trial.
- **2025-11** — Rondo researchers presented additional preclinical characterization of RNDO-564 at SITC.
- **2025-04** — Peer-reviewed preclinical RNDO-564 findings appeared in Journal for ImmunoTherapy of Cancer.

## Links

- Website: https://www.rondotx.com/
- LinkedIn: https://www.linkedin.com/company/rondotx

---

Profile page: https://yespress.io/rondo-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-09-30